Background Erlotinib has been shown to improve progression-free survival compared with
chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung …

Purpose: Concomitant genetic alterations could account for transient clinical responses to
tyrosine kinase inhibitors of the EGF receptor (EGFR) in patients harboring activating EGFR …

Background: Programmed death-ligand 1 (PD-L1) may be induced by oncogenic signals or
can be upregulated via interferon gamma (IFN-γ). We have explored whether the expression …

Importance The EURTAC trial demonstrated the greater efficacy of erlotinib compared with
chemotherapy for the first-line treatment of European patients with advanced non–small-cell …

Purpose: Non-small-cell lung cancers harboring EML4-ALK rearrangements are sensitive to
crizotinib. However, despite initial response, most patients will eventually relapse, and …

Non-small-cell lung cancer patients with activating epidermal growth factor receptor (EGFR)
mutations typically benefit from EGFR tyrosine kinase inhibitor treatment. However, virtually …

Background The efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) in EGFR-mutant non–small cell lung cancer (NSCLC) is limited by adaptive …

Importance Therapies targeting the programmed cell death 1 (PD-1) receptor or its ligand (PD-L1),
such as the humanized monoclonal antibody durvalumab, have shown durable …

Epidermal growth factor receptor (EGFR)-mutation-positive non-small cell lung cancer (NSCLC)
is incurable, despite high rates of response to EGFR tyrosine kinase inhibitors (TKIs). …

BRAFV600E is a unique molecular marker for metastatic melanoma, being the most frequent
somatic point mutation in this malignancy. Detection of BRAFV600E in blood could have …